Blog

Critical Survey: Arena Pharmaceuticals (ARNA) and Editas Medicine (NASDAQ:EDIT) – The Ledger Gazette

Critical Survey: Arena Pharmaceuticals (ARNA) and Editas Medicine (NASDAQ:EDIT)
The Ledger Gazette
It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9
Reviewing Editas Medicine (EDIT) & Enanta Pharmaceuticals …StockNewsTimes


Financial Newsletter – ZacksZacks
SEC FORM 4 – SEC.govSEC.gov

all 17 news articles »

2018-02-20 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.